Structure Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Structure Therapeutics Inc. (GPCR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 4.72 million shares for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-02-26
- Structure Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-12-31 was 1.51M shares, a 333.52% increase year-over-year.
- Structure Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-09-30 was 372.00K shares, a 8.77% increase year-over-year.
- Structure Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-06-30 was 780.00K shares, a 273.21% increase year-over-year.
- Structure Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-03-31 was 2.06M shares, a 54.85% decline year-over-year.
- Structure Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 4.72M shares, a 13.41% decline from fiscal 2023.
- Structure Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 5.45M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | 1.51M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 1.89M shares derived: sum of 2 quarters · filed 2026-02-26 | 2.67M shares derived: sum of 3 quarters · filed 2026-02-26 | 4.72M shares 10-K · filed 2026-02-26 | 3.68M shares 10-K · filed 2025-02-27 |
| 2024-09-30 | 372.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 1.15M shares derived: sum of 2 quarters · filed 2024-11-13 | 3.21M shares 10-Q · filed 2024-11-13 | 3.56M shares derived: sum of 4 quarters · filed 2024-11-13 | |
| 2024-06-30 | 780.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 2.83M shares 10-Q · filed 2024-08-08 | 3.18M shares derived: sum of 3 quarters · filed 2024-08-08 | 3.53M shares derived: sum of 4 quarters · filed 2024-08-08 | |
| 2024-03-31 | 2.06M shares 10-Q · filed 2024-05-09 | 2.40M shares derived: sum of 2 quarters · filed 2024-05-09 | 2.75M shares derived: sum of 3 quarters · filed 2024-05-09 | 2.96M shares derived: sum of 4 quarters · filed 2024-05-09 | |
| 2023-12-31 | 349.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | 691.00K shares derived: sum of 2 quarters · filed 2024-03-08 | 900.00K shares derived: sum of 3 quarters · filed 2024-03-08 | 5.45M shares 10-K · filed 2024-03-08 | |
| 2023-09-30 | 342.00K shares derived: 10-Q 9 month − 10-Q/A 6 month · filed 2023-11-17 | 551.00K shares derived: sum of 2 quarters · filed 2023-11-17 | 5.10M shares 10-Q · filed 2023-11-17 | ||
| 2023-06-30 | 209.00K shares derived: 10-Q/A 6 month − 10-Q 3 month · filed 2023-11-17 | 4.76M shares 10-Q/A · filed 2023-11-17 | |||
| 2023-03-31 | 4.55M shares 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |